Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Mpeg La L L C maintains 3 pending office actions focused in the Biotechnology & Pharmaceuticals technology area. These matters are handled by 3 distinct examiners, which shows that each pending action is currently under the review of a different individual. Despite the variety of examiners, the portfolio is concentrated within 2 distinct art units, suggesting that the underlying technologies share technical commonalities despite the individual examiner assignments.
KONOPELSKI SNAVEL, SARA ELIZABETH is identified as the busiest examiner for this portfolio, currently managing 1 pending office action. Because there are 3 pending office actions and 3 distinct examiners, the workload is distributed so that each examiner oversees 1 matter. This distribution across 2 distinct art units indicates that the Biotechnology & Pharmaceuticals filings are being processed through closely related administrative channels. For practitioners, the action assigned to the busiest examiner represents a balanced allocation of resources across the 3 active matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 33.3% | +38.9% |
| ZARA, JANE J | 1 | 71.0% | +16.1% |
| ALLEN, SARAH ELIZABETH | 1 | 57.1% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17925807 | ORTHOGONALLY LINKED MULTIMERIC OLIGONUCLEOTIDES | ZARA, JANE J | 54d |
| 18032118 | LINKER COMPOUNDS COMPRISING AMIDE BONDS | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 17923843 | LINKER COMPOUNDS | ALLEN, SARAH ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17925807 | ORTHOGONALLY LINKED MULTIMERIC OLIGONUCLEOTIDES | ZARA, JANE J | 54d |
| 18032118 | LINKER COMPOUNDS COMPRISING AMIDE BONDS | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 17923843 | LINKER COMPOUNDS | ALLEN, SARAH ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18032118 | LINKER COMPOUNDS COMPRISING AMIDE BONDS | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §101§102§103§112DP | Non-Final OA | — | Pending | Apr 14, 2023 |
| 17925807 | ORTHOGONALLY LINKED MULTIMERIC OLIGONUCLEOTIDES | ZARA, JANE J | 1637 | §103§112 | Non-Final OA | 54d | Pending | Nov 16, 2022 |
| 17923843 | LINKER COMPOUNDS | ALLEN, SARAH ELIZABETH | 1637 | §102§103§112 | Final Rejection | — | Pending | Nov 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial